STIL centriolar assembly proteinGenealiases: MCPH7 · SIL
Q-omics provides the consensus-scored STIL profile across patient tissues and cancer cell-line models. STIL expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STIL is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, STIL protein abundance shows 26,178 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where STIL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STIL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STIL survival associations across molecular data types. STIL RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STIL RNA expression–survival associations across cancer types. High STIL expression shows unfavorable associations in ACC, MESO, KIRP, LIHC, KICH and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STIL RNA expression.
This table summarizes STIL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STIL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STIL shows higher tumor expression in BLCA, HNSC, COAD, KIRP, KIRC and LUAD. The BLCA box plot shows higher STIL RNA expression in tumor versus normal tissue (log2 FC = +2.311, t-test p < 0.001).
This table shows molecular features associated with STIL in patient tissues and cancer cell lines. In patient samples, STIL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STIL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
